Levofloxacin Hydrochloride and Glucose Injection

This product is the levorotatory form of ofloxacin, and its antibacterial activity is about twice that of ofloxacin. Its main mechanism of action is to inhibit bacterial DNA gyrase activity and inhibit bacterial DNA replication. This product has the characteristics of a broad antibacterial spectrum and strong antibacterial effect. It has strong antibacterial activity against most Enterobacteriaceae, such as Klebsiella pneumoniae, Proteus, Salmonella typhi, Shigella, and some Escherichia coli. It also has good antibacterial effects on some Staphylococci, Streptococcus pneumoniae, Chlamydia, etc.

The main ingredients of this product are levofloxacin hydrochloride and glucose. Chemical name: (S)-(-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-l-piperazinyl)-7-oxo-7H-pyridinyl[1,2,3,-de]-[1,4]benzoxazine-6-carboxylic acid hydrochloride-crystalline hydrate, glucose. Chemical structure of levofloxacin hydrochloride: Chemical structure of glucose: Molecular formulas are: C18H20FN3O4HCIH2O, C6H12O6·H2O Molecular weights are: 415.85198.17

This product is a light yellow-green clear liquid.

This product is suitable for the following moderate and severe infections caused by sensitive bacteria: 1. Respiratory system infections: acute bronchitis, acute exacerbation of chronic bronchitis, diffuse bronchiolitis, bronchiectasis complicated by infection, pneumonia, tonsillitis (peritonsillar abscess); 2. Urinary system infections: pyelonephritis, complicated urinary tract infection, etc.; 3. Reproductive system infections: acute prostatitis, acute epididymitis, uterine cavity infection, uterine adnexitis, pelvic inflammatory disease (metronidazole can be used in combination when anaerobic bacteria infection is suspected); 4. Skin and soft tissue infections: infectious impetigo, cellulitis, lymphangitis (adenitis), subcutaneous abscess, perianal abscess, etc.; 5. Intestinal infections: bacterial dysentery, infectious enteritis, Salmonella enteritis, typhoid and paratyphoid; 6. Various infections in patients with sepsis, neutropenia and immunodeficiency; 7. Other infections: mastitis, trauma, burns and postoperative wound infection, abdominal infection (use metronidazole in combination when necessary), cholecystitis, cholangitis, bone and joint infections, and ENT infections, etc.

Intravenous drip: 0.4 g (4 bottles) per day for adults, divided into 2 intravenous drips. For patients with severe infections and those whose pathogens are less sensitive to this product (such as Pseudomonas aeruginosa), the maximum daily dose can be increased to 0.6 g (6 bottles), divided into 2 intravenous drips.

During medication, symptoms such as nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, and bloating may occur; neurological symptoms such as insomnia, dizziness, and headache; rash, itching, erythema, and redness, itching, or phlebitis at the injection site may occur. Transient liver function abnormalities may also occur, such as increased blood transaminase and increased serum total bilirubin. The incidence of the above adverse reactions is between 0.1 and 0.5%. Occasionally, blood urea nitrogen rises, fatigue, fever, palpitations, and abnormal taste may occur, which are generally tolerated and disappear quickly after the end of the course of treatment.

It is contraindicated for patients who are allergic to quinolones, pregnant or lactating women, and patients under 18 years of age.

Precautions for children: Not for use in patients under 18 years of age. Precautions for pregnancy and lactation: Not for use in pregnant or lactating women.

This product cannot be used in the same infusion tube with multivalent metal ion solutions such as magnesium and calcium. Avoid using it simultaneously with theophylline. If it is necessary to use it simultaneously, the blood concentration of theophylline should be monitored and the dosage should be adjusted accordingly. When used simultaneously with warfarin or its derivatives, the prothrombin time or other coagulation tests should be monitored. When used simultaneously with non-steroidal anti-inflammatory drugs, convulsions may be induced. When used simultaneously with oral hypoglycemic drugs, blood sugar disorders, including hyperglycemia and hypoglycemia, should be caused. Therefore, blood sugar concentrations should be monitored during medication. Once hypoglycemia occurs, this product should be discontinued immediately and appropriate treatment should be given.

Keep in a dark, cool (not exceeding 20℃) and dry place with airtight storage.

100ml: 0.1g levofloxacin and 5g glucose

24 months

Jinling Pharmaceutical Co.,ltd.zhejiang Tianfeng Pharmaceutical FACTORY

• Founded in:

  1998-10-29

• Address:

  Room 402, No. 2318, Wangmushan Road, Nantaihu Biomedicine Industrial Park, Huzhou City, Zhejiang Province (self-declaration)

• Tax NO.:

  91330501719546709G

• Registered Funds:

  -

• Email:

  Log in to view